Artiva Biotherapeutics

Artiva develops natural killer (NK) cell-based therapies for patients with devastating autoimmune diseases.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2024
Stage of Initial Investment
Series A
Initial Investment Year
2020
Artiva Portco Hover Image2